Oakrum Pharma has entered into an agreement with Biophore India Pharmaceuticals to develop and manufacture two prescription generic pharmaceutical products that are intended to be commercialized in the U.S. under the Oakrum label. It is anticipated that both products will be sold through the specialty distribution market channel. The total market for the products in the U.S. exceeded $150 million in aggregate sales for the 12-month period ending December 31, 2018 according to Bloomberg® data.
"The partnership with Biophore will provide a vertically integrated solution to our growing product development pipeline,” Marco Polizzi, CEO of Oakrum, said. “Oakrum's vision to focus on underserved patient populations is in direct alignment with that of Biophore's. Biophore provides unique API and finished dosage form product development capabilities which are expected to further contribute to Oakrum's objective of bringing more affordable specialty and rare disease prescription products to market."
"We are partnering with Oakrum on these products because of our aligned focus to serve niche product markets and because of their focus and commercial expertise within the specialty product marketplace."